← All supplements
Limited evidenceLongevity & antioxidants

PQQ

Pyrroloquinoline quinone is marketed on impressive mitochondrial biology that has not translated into convincing human outcomes. A handful of small cognitive trials, almost all run or funded by the ingredient makers, report gains on selected test scores; the one supervised training trial found no performance benefit, and claims for sleep, energy and inflammation rest on open-label or tiny studies.

Where to buy

  • iHerb Store search for “pqq pyrroloquinoline quinone” Ships to 180+ countries · welcome discount for new customers
    View on iHerb

Each store sells its own product: check brand, amount and price on the store page before buying. Prices change; the date shows when we last checked.

Referral link — this site may earn a commission on purchases.

What the science says

  • Cognitive function Limited evidence

    Three small double-blind trials of PQQ disodium salt at about 20 mg/day for 12 weeks reported better scores than placebo on some memory, attention or flexibility tests, and a 2024 trial in mild cognitive impairment found a better orientation score with a PQQ plus hydrogen blend. Each trial measured many outcomes, the positive ones differ from study to study, and nearly all were funded or run by ingredient manufacturers.

    Who was studied
    Healthy Japanese adults aged 20 to 65 (Tamakoshi 2023) and 40 to 80 (64 randomized, 58 completers; Shiojima 2022), 41 healthy older Japanese adults (Itoh 2016), and 34 older adults with mild cognitive impairment, 28 of them women, given a PQQ blend with hydrogen-producing minerals (Baltic 2024).
    Result
    Computerized cognitive batteries (Cognitrax, Stroop, Touch M) after 12 weeks, and BDNF, ADAS-Cog and brain imaging after 6 weeks in the cognitive impairment trial; PQQ groups improved on selected subdomains such as composite and verbal memory, reaction time and attention.
    Effect size
    The abstracts report statistical significance rather than effect sizes. In the cognitive impairment trial the BDNF difference versus placebo was not significant (interaction P = 0.14), the ADAS-Cog orientation domain favored the blend (P = 0.03), and cerebral oxygen saturation rose from 48.4% to 52.8% within the treated group.
    Limitations
    Small samples, many outcomes without reported correction for multiple testing, subdomain results that do not replicate across trials, and funding or authorship by PQQ manufacturers; the cognitive impairment trial tested a blend, so PQQ alone cannot be credited.
    Sources
    [1] [2] [3] [4]
  • Mitochondrial biogenesis and exercise performance Limited evidence

    In untrained men doing six weeks of supervised endurance training, 20 mg/day of PQQ did not improve aerobic performance or body composition more than placebo, although PGC-1α protein, a marker of mitochondrial biogenesis, rose more. A 2026 trial of a single 20 mg dose before exhaustive treadmill exercise reported a change in only one questionnaire domain of body awareness and no performance benefit.

    Who was studied
    23 untrained men randomized to 20 mg/day of PQQ or placebo during a six-week supervised endurance program (Hwang 2020), and 60 participants given a single 20 mg dose of PQQ, 300 mg of NMN, both, or placebo before a Bruce treadmill test (Zhao 2026).
    Result
    VO2peak, test duration, body composition by DEXA and PGC-1α protein after training; interoception questionnaires (BPQ, MAIA) after acute exhaustive exercise.
    Effect size
    No between-group difference in aerobic performance or body composition (p > 0.05), while PGC-1α protein rose significantly more with PQQ (p < 0.05). In the acute trial only the Body Listening domain showed a group-by-time interaction (p = 0.016).
    Limitations
    Very small samples, short duration, and a biomarker change without any functional benefit; the acute trial relied on subjective questionnaires and did not show better exercise capacity.
    Sources
    [5] [6]
  • Sleep and fatigue Limited evidence

    Reports of better sleep and mood with PQQ come from an open-label trial summarized in a 2024 review by scientists from the ingredient maker; no placebo-controlled trial has confirmed them. Without blinding and a control group these findings are hypothesis-generating only.

    Who was studied
    Adults in an uncontrolled, open-label study of PQQ disodium salt, as summarized in a 2024 narrative review written by scientists from the manufacturer.
    Result
    Self-rated sleep quality and mood questionnaires, which improved from baseline.
    Effect size
    There is no placebo comparison, so no effect attributable to PQQ can be estimated.
    Limitations
    Open-label design, self-reported outcomes highly prone to placebo and expectation effects, and evidence that reaches us through a manufacturer-authored review rather than an independent trial.
    Sources
    [7]
  • Inflammation and blood markers Limited evidence

    In a 10-person crossover study, about three days of daily PQQ lowered plasma C-reactive protein and IL-6 and shifted urinary metabolites, without changing cholesterol, glucose or other routine blood tests. Marker changes in 10 people over a few days say nothing about health outcomes.

    Who was studied
    10 healthy adults (5 women, 5 men) in a crossover study, given a single dose of 0.2 mg/kg and then 0.3 mg/kg per day of PQQ in a fruit drink.
    Result
    Plasma CRP and IL-6, standard lipid and glucose panels, and urinary metabolites after 76 hours of daily intake.
    Effect size
    CRP and IL-6 fell significantly and routine clinical indices were unchanged; the abstract gives no magnitudes.
    Limitations
    Tiny, very short study without a placebo arm, measuring surrogate markers; it has not been repeated in a larger controlled trial.
    Sources
    [8]

Dosage & safety

Studied doseHuman trials almost all use 20 mg/day of PQQ disodium salt, taken with food, for 6-12 weeks. There is no evidence that higher doses do more, and the training trial that found no performance benefit used the same 20 mg/day. 20 mg/day is also the maximum intake the EU authorized when it approved PQQ as a novel food.
SafetyNo serious adverse events have been reported at about 20 mg/day over 12 weeks; occasional headache, GI upset and sleep changes (both drowsiness and difficulty sleeping) occur at rates similar to placebo. The EU food safety authority judged 20 mg/day safe for healthy adults but excluded pregnant and breastfeeding women, and long-term human data beyond a few months do not exist. In rats, high doses raised kidney weight and urinary protein in females (reversible), so do not megadose. Not studied in children.

How to take it

TimingTiming does not matter.
With food?With food, as in essentially all the human trials.
Worth knowing20 mg/day is the ceiling that has been tested in humans, and rodent work shows kidney effects at very high doses — there is no reason to megadose.

Frequently asked questions

Does PQQ boost mitochondria or energy?

Not in humans so far: 20 mg/day of PQQ for three weeks produced no improvement in VO2 max, aerobic performance or markers of mitochondrial biogenesis versus placebo. The mitochondrial claims for PQQ rest on cell and rodent studies, so the evidence is limited.

Does PQQ improve memory or brain function?

The evidence is limited: small, manufacturer-funded trials of about 20 mg/day of PQQ for 12 weeks reported gains in only selected scores or subtests. These results are suggestive at best.

How much PQQ should I take?

Human trials used 10-20 mg/day of PQQ disodium salt with food, and there is no evidence higher doses do more. Do not megadose: 20 mg/day is the highest tested, and rodent studies at very high doses showed kidney effects.

Is PQQ safe to take long term?

No serious adverse events have been reported with PQQ at 20 mg/day over 12 weeks, but long-term human safety data beyond a few months do not exist. PQQ has not been studied in pregnancy, breastfeeding or children.

Scientific references

  1. Pyrroloquinoline quinone disodium salt improves brain function in both younger and older adults.
    Tamakoshi M, Suzuki T, Nishihara E, et al. — Food Funct, 2023
  2. Effect of Dietary Pyrroloquinoline Quinone Disodium Salt on Cognitive Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.
    Shiojima Y, Takahashi M, Takahashi R, et al. — J Am Nutr Assoc, 2022
  3. Effect of the Antioxidant Supplement Pyrroloquinoline Quinone Disodium Salt (BioPQQ™) on Cognitive Functions.
    Itoh Y, Hine K, Miura H, et al. — Adv Exp Med Biol, 2016
  4. The impact of six-week dihydrogen-pyrroloquinoline quinone supplementation on mitochondrial biomarkers, brain metabolism, and cognition in elderly individuals with mild cognitive impairment: a randomized controlled trial.
    Baltic S, Nedeljkovic D, Todorovic N, et al. — J Nutr Health Aging, 2024
  5. Effects of Pyrroloquinoline Quinone (PQQ) Supplementation on Aerobic Exercise Performance and Indices of Mitochondrial Biogenesis in Untrained Men.
    Hwang PS, Machek SB, Cardaci TD, et al. — J Am Coll Nutr, 2020
  6. The effects of pyrroloquinoline quinone and nicotinamide mononucleotide supplementation on interoception following acute exhaustive exercise: a randomised, double-blind, placebo-controlled study.
    Zhao C, Wu B, Sui H, et al. — Sci Rep, 2026
  7. The effects of pyrroloquinoline quinone disodium salt on brain function and physiological processes.
    Ikemoto K, Mohamad Ishak NS, Akagawa M — J Med Invest, 2024
  8. Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects.
    Harris CB, Chowanadisai W, Mishchuk DO, et al. — J Nutr Biochem, 2013

Related in Longevity & antioxidants